Kallyope
Business Services · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
430 E 29th St Fl 10, New York, New York,...Website
www.kallyope.comRevenue
$15.1 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
3
1
1
1
2
1
About Kallyope
Kallyope, headquartered at the Alexandria Center® for Life Science in New York City, is a leading biotechnology company focused on identifying and pursuing novel therapeutics involving the gut-brain axis. The company's cross-disciplinary team integrates advanced technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that leads to transformational therapeutics to improve human health.Explore more
Kallyope Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kallyope your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Kallyope launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Kallyope is spiking on competitors!
Check if Kallyope has recently received funding, and reach out quickly before it becomes old news!
Click to see if Kallyope had a recent Job posting/layoffs
Earning: See what the market has to say on Kallyope recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Kallyope
Kallyope, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Kallyope has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Kallyope
Compare insights from companies similar to Kallyope, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Kallyope is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Kallyope is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Kallyope.
Kallyope financials insights
Gather financial insights about Kallyope, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Private Equity
$28.1M
Series A
$44M
2018
Series B
$66M
2020
Series C
$112M
2022
Series D
$236M
Kallyope Tech Stack
A closer look at the technologies used by Kallyope
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Project
Laboratory Operations, Medical Research, Clinical Operations
Kallyope News & Media
Novo Nordisk Acquires Three Obesity R&D Programs from Kallyope – Non-Incretin Assets ...
Novo Nordisk A/S (NYSE: NVO) announced that it has acquired three brand‑new obesity research and development programs from New York‑based biotech company Kallyope. Jacob Petersen, head of global research at Novo Nordisk, wrote in a LinkedIn post that one program is a “potential first‑in‑class peptide,” another is a “follow‑on small molecule” targeting a novel target, and the third is a “small molecule receptor agonist.”Kallyope Announces License Agreement with Novo Nordisk
NEW YORK--(BUSINESS WIRE)--Kallyope, a clinical stage biotechnology company discovering and developing novel therapies for diseases with high unmet need, today announced that under the terms of its research collaboration with Novo Nordisk to discover novel peptide therapeutics, a ligand identified by Kallyope has been licensed by Novo Nordisk for further development, including as a potential new mechanism for the treatment of obesity. This is a significant scientific milestone stemming from theKallyope Enters Phase 2 With First-in-class Oral Approach for the Treatment of Both Obesity and Type 2 Diabetes
NEW YORK--(BUSINESS WIRE)--Kallyope announces the initiation of a Phase 2 clinical trial evaluating two novel nutrient receptor agonists in both obesity and Type 2 diabetes.Kallyope Appoints Franz Humer, Ph.D., as Chair of its Board of Directors
NEW YORK--(BUSINESS WIRE)--Kallyope announces the appointment of Franz Humer, Ph.D., as chair of its board of directors.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Kallyope
Sign Up For FreeTo access detailed company insights
Kallyope, headquartered at the Alexandria Center® for Life Science in New York City, is a leading biotechnology company focused on identifying and pursuing novel therapeutics involving the gut-brain axis. The company's cross-disciplinary team integrates advanced technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biol... Read More
